This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea Biopharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB)

Q2 2012 Earnings Call

August 7, 2012 8:00 AM ET


Brent Larson – SVP, CFO, Treasurer and Secretary

Mark Pykett – President and CEO

Fred Cope – SVP, Pharmaceutical Research and Clinical Development

Tom Tulip – EVP and Chief Business Officer


Charles Duncan – JMP Securities

Kevin DeGeeter – Ladenburg Thalmann

Mike King – Rodman & Renshaw

Stephen Dunn – Life Tech Capital

Steve Brozak – WBB Securities

Dalton Chandler – Needham & Co

Spencer Nam – ThinkEquity



Greetings and welcome to the Navidea Biopharmaceuticals, Incorporated Second Quarter 2012 Conference Call. At that time, all participants are in a listen-only mode. A brief question-and-answer session will follow the following presentation. (Operator Instructions) As a reminder, this conference is being recorded. Also management would like to alert you that today’s conference will be no more than one hour in duration.

It is now my pleasure at this time to introduce your host, Brent Larson, CFO of Navidea Biopharmaceuticals, Incorporated. Thank you, Mr. Larson. You may now begin.

Brent Larson

Thank you, Rob. Good morning, everyone. My name, as Rob said, is Brent Larson. I’m the CFO of Navidea Biopharmaceuticals, and I’ll be moderating this morning’s call.

Before we get started with the formal comments, we’d like to remind you that during the course of this call management may make projections or other forward-looking remarks regarding future events or the future financial performance of the company.

It’s important to note that such statements about Navidea’s estimated or anticipated future results or other non-historical facts are forward-looking statements and reflect Navidea’s current perspective on existing trends and information. Navidea disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Navidea’s current expectations depending on a number of factors affecting Navidea’s business.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs